JNJ vs. KYMR: Johnson & Johnson vs. Kymera Therapeutics Stock Comparison

Company Profile

Johnson & Johnson (JNJ) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JNJ is classified in Pharmaceuticals while KYMR is classified in Biotechnology.

Johnson & Johnson (JNJ) has more than two decades of public-market history since January 2, 1962, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Johnson & Johnson (JNJ) is defensive at 0.21 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Johnson & Johnson (JNJ) reports 20.02%, ranking against industry peers normally.

Johnson & Johnson (JNJ) at 16.20% retains a top-quartile share of revenue as profit, ahead of Kymera Therapeutics (KYMR) at 0.00%, which keeps about the industry-typical share.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Johnson & Johnson (JNJ) reports 25.74%, ranking against industry peers normally.

Profitability Metrics

Growth

Johnson & Johnson (JNJ) at 6.05% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Johnson & Johnson (JNJ) reports EPS growth of 90.50%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.

Both Johnson & Johnson (JNJ) at 0.55 and Kymera Therapeutics (KYMR) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Kymera Therapeutics (KYMR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

Kymera Therapeutics (KYMR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Johnson & Johnson (JNJ) trades at 41.92 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Johnson & Johnson (JNJ) at 6.69 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Both Johnson & Johnson (JNJ) at 8.16 and Kymera Therapeutics (KYMR) at 6.96 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics